Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles

References

• TravisSPDaneseSKupcinskasLOnce-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyGut201463343344123436336
   PubMed Web of Science ®Google Scholar
• FrankDNSt AmandALFeldmanRABoedekerECHarpazNPaceNRMolecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseasesProc Natl Acad Sci U S A200710434137801378517699621
   PubMed Web of Science ®Google Scholar
• KnutsonCGMangerichAZengYChemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel diseaseProc Natl Acad Sci U S A201311026E2332E234123754421
   PubMed Web of Science ®Google Scholar
• SeowCHBenchimolEIGriffithsAMOtleyARSteinhartAHBudesonide for induction of remission in Crohn’s diseaseCochrane Database Syst Rev20083CD00029618646064
   PubMedGoogle Scholar
• NakaseHOkazakiKTabataYDevelopment of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategyJ Pharmacol Exp Ther20002921152110604927
   PubMed Web of Science ®Google Scholar
• TrommABunganičITomsováEBudesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s diseaseGastroenterology20111402425.e1434.e121070781
   PubMed Web of Science ®Google Scholar
• LautenschlägerCSchmidtCFischerDStallmachADrug delivery strategies in the therapy of inflammatory bowel diseaseAdv Drug Deliv Rev201471587624157534
   PubMed Web of Science ®Google Scholar
• FriendDRNew oral delivery systems for treatment of inflammatory bowel diseaseAdv Drug Deliv Rev200557224726515555741
   PubMed Web of Science ®Google Scholar
• SandbornWJTravisSMoroLOnce-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I studyGastroenterology2012143512181226.e1e222892337
   PubMed Web of Science ®Google Scholar
• GrossVBunganicIBelousovaEA3 g Mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trialJ Crohns Colitis20115212913821453882
   PubMed Web of Science ®Google Scholar
• HongSYumSYooHJColon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitisMol Pharm2012951310131922428658
   PubMedGoogle Scholar
• ZhuQTaltonJZhangGLarge intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infectionNat Med20121881291129622797811
   PubMed Web of Science ®Google Scholar
• NaeemMKimWCaoJJungYYooJWEnzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colonColloids Surf B Biointerfaces201412327127825266978
   PubMed Web of Science ®Google Scholar
• BigelowHRobinsonDAzobenzeneOrganic Synth19422228
   Google Scholar
• YooJWGiriNLeeCHpH-sensitive Eudragit nanoparticles for mucosal drug deliveryInt J Pharm20114031–226226720971177
   PubMed Web of Science ®Google Scholar
• KrishnamachariYMadanPLinSDevelopment of pH-and time-dependent oral microparticles to optimize budesonide delivery to ileum and colonInt J Pharm2007338123824717368982
   PubMedGoogle Scholar
• VandammeTFLenourryACharrueauCChaumeilJCThe use of polysaccharides to target drugs to the colonCarbohydr Polym2002483219231
   Web of Science ®Google Scholar
• NiebelWWalkenbachKBéduneauAPellequerYLamprechtANanoparticle-based clodronate delivery mitigates murine experimental colitisJ Control Release2012160365966522445727
   PubMed Web of Science ®Google Scholar
• MorrisGPBeckPLHerridgeMSDepewWTSzewczukMRWallaceJLHapten-induced model of chronic inflammation and ulceration in the rat colonGastroenterology19899637958032914642
   PubMed Web of Science ®Google Scholar
• HartmannGBidlingmaierCSiegmundBSpecific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in miceJ Pharmacol Exp Ther20002921223010604928
   PubMed Web of Science ®Google Scholar
• MakhlofATozukaYTakeuchiHpH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat modelEur J Pharm Biopharm20097211819348015
   PubMed Web of Science ®Google Scholar
• WeigmannBLehrHAYancopoulosGThe transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitisJ Exp Med200820592099211018710929
   PubMed Web of Science ®Google Scholar
• LamprechtAYamamotoHTakeuchiHKawashimaYA pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticlesJ Control Release2005104233734615907584
   PubMed Web of Science ®Google Scholar
• MezzenaMScaliaSYoungPMTrainiDSolid lipid budesonide micropar-ticles for controlled release inhalation therapyAAPS J200911477177819908147
   PubMed Web of Science ®Google Scholar
• LamprechtASchäferULehrCMSize-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosaPharm Res200118678879311474782
   PubMed Web of Science ®Google Scholar
• ThiesenAWildGTappendenKThe locally acting glucocor-ticosteroid budesonide enhances intestinal sugar uptake following intestinal resection in ratsGut200352225225912524409
   PubMed Web of Science ®Google Scholar
• YadavVGaisfordSMerchantHABasitAWColonic bacterial metabolism of corticosteroidsInt J Pharm2013457126827424055438
   PubMedGoogle Scholar
• MendozaJAbreuMBiological markers in inflammatory bowel disease: practical consideration for cliniciansGastroenterol Clin Biol200933Suppl 3S158S17320117339
   PubMedGoogle Scholar
• AliHWeigmannBNeurathMCollnotEWindbergsMLehrCMBudesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseasesJournal of Controlled Release201418316717724685705
   PubMed Web of Science ®Google Scholar
• UlbrichWLamprechtATargeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseasesJ R Soc Interface20107Suppl 1S55S6619940000
   PubMed Web of Science ®Google Scholar
• LamprechtAIBD: selective nanoparticle adhesion can enhance colitis therapyNat Rev Gastroenterol Hepatol20107631131220523352
   PubMed Web of Science ®Google Scholar
• LamprechtAYamamotoHTakeuchiHKawashimaYNanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in ratsJ Pharmacol Exp Ther2005315119620215980057
   PubMed Web of Science ®Google Scholar
• SchmidtCLautenschlaegerCCollnotEMNano- and microscaled particles for drug targeting to inflamed intestinal mucosa – first in vivo study in human patientsJ Control Release2013165213914523127508
   PubMed Web of Science ®Google Scholar